Objective: To discuss the clinical efficacy of Gegen Qinlian pills in the treatment of COVID-19. Methods: from February 23 to March 15, 2020, 118 patients with COVID-2019 were enrolled in Hubei traditional Chinese medicine hospital. According to the treatment method, 60 cases were divided into the control group and 58 cases were divided into the treatment group. The control group was given routine treatment, and the treatment group was added with GegenQinlian Pill on the basis of the control group. The time of antipyretic, the time of nucleic acid turning negative, the rate of turning severe, the mortality, the clinical effect and the change of symptom score before and after treatment were observed. Results: The main symptoms of fever, cough and fatigue in the treatment group and the control group after treatment were significantly different from those before treatment (P<0.05).In the treatment group, cough, chest tightness, nausea, vomiting and loose stool were improved significantly (P<0.05). The gastrointestinal symptom score and total symptom score of the two groups were significantly reduced after treatment, with a significant difference compared with before treatment (P<0.05), and there was a significant difference between the treatment group and the control group after treatment (P<0.05). The improvement rate of tongue quality and tongue coating in the control group was 65.71% and 55.56%, respectively. The improvement rate of tongue quality and tongue coating in the treatment group was 72.09% and 66.66% respectively. After treatment, the leukocyte count and lymphocyte absolute value of the control group were significantly different from those before treatment (P<0.05), and there was significant difference between the treatment group and the control group after treatment (P<0.05). There was no significant difference in hs-CRP between the control group and the treatment group before treatment (P >0.05), but there was a significant difference in CRP between the two groups after treatment and before treatment (P<0.05), and a significant difference between the treatment group and the control group after treatment (P<0.05). The antipyretic time was 3 (2.25, 3.5) days in the control group and 3 (2,4.5) days in the treatment group. There was no significant difference in the antipyretic time between the two groups (P >0.05).The new group coronavirus nucleic acid negative time in control group was 10.5 (8,13) days, the treatment group was 8 (5.75, 11.25) days, and the new group coronal virus nucleic acid negative time in two group had significant difference (P<0.05).In the lung CT,52 cases (86.67%) in the control group and 52 cases (89.66%) in the treatment group significantly improved than that before the treatment, which were mainly manifested in the focus area decreased, color became thinner and lighter.After treatment, the patients in the two groups reached the discharge standard. There were 0 cases of invalid, 0 cases of death, and 0 cases of transformation from light and common type to heavy and critical type. There were 0 cases in the transformation from light type to heavy type and critical type.There was no abnormal liver and kidney function during the treatment. All the patients did not show any other uncomfortable symptoms or aggravated signs except the original symptoms of digestive tract and respiratory tract.Conclusion: Gegen Qinlian pill can actively improve the clinical symptoms of COVID-19 patients, It has a better therapeutic effect on gastrointestinal symptoms, and are safe and reliable for use,which is worth further promotion in clinical practice.